Market Closed -
Nasdaq
04:00:00 2024-05-15 pm EDT
|
5-day change
|
1st Jan Change
|
1.4
USD
|
+5.26%
|
|
-15.15%
|
-25.93%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
275.4
|
684.6
|
383.1
|
81.58
|
115
|
-
|
-
|
Enterprise Value (EV)
1 |
275.4
|
684.6
|
383.1
|
81.58
|
115
|
115
|
115
|
P/E ratio
|
-2.8
x
|
-8.75
x
|
-5.26
x
|
-0.57
x
|
-0.94
x
|
-0.83
x
|
-0.77
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
15.4
x
|
70.4
x
|
15.3
x
|
-
|
18.4
x
|
13.8
x
|
9.2
x
|
EV / Revenue
|
15.4
x
|
70.4
x
|
15.3
x
|
-
|
18.4
x
|
13.8
x
|
9.2
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-10.8
x
|
-
|
-0.83
x
|
-1.53
x
|
-1.35
x
|
-1.26
x
|
FCF Yield
|
-
|
-9.29%
|
-
|
-120%
|
-65.2%
|
-74.1%
|
-79.5%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
19,601
|
39,143
|
42,851
|
43,165
|
82,170
|
-
|
-
|
Reference price
2 |
14.05
|
17.49
|
8.940
|
1.890
|
1.400
|
1.400
|
1.400
|
Announcement Date
|
3/11/21
|
3/15/22
|
3/15/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
17.9
|
9.73
|
24.99
|
-
|
6.25
|
8.333
|
12.5
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-39.19
|
-61.43
|
-72.55
|
-152
|
-129.1
|
-126.4
|
-137.9
|
Operating Margin
|
-218.91%
|
-631.38%
|
-290.32%
|
-
|
-2,065.68%
|
-1,516.71%
|
-1,103.05%
|
Earnings before Tax (EBT)
1 |
-39.49
|
-62.12
|
-69.79
|
-142.7
|
-120.4
|
-121.3
|
-134.8
|
Net income
1 |
-36.68
|
-62
|
-69.79
|
-142.7
|
-120.4
|
-121.3
|
-134.8
|
Net margin
|
-204.87%
|
-637.19%
|
-279.27%
|
-
|
-1,926.37%
|
-1,455.47%
|
-1,078.14%
|
EPS
2 |
-5.010
|
-2.000
|
-1.700
|
-3.310
|
-1.488
|
-1.685
|
-1.830
|
Free Cash Flow
1 |
-
|
-63.59
|
-
|
-98.18
|
-75
|
-85.2
|
-91.5
|
FCF margin
|
-
|
-653.51%
|
-
|
-
|
-1,200%
|
-1,022.4%
|
-732%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/21
|
3/15/22
|
3/15/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
5.468
|
24.99
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-15.54
|
4.706
|
-22.71
|
-22.98
|
-31.56
|
-33.32
|
-34.89
|
-52.26
|
-31.57
|
-30.87
|
-31.98
|
-32.65
|
-33.4
|
-36.5
|
-37.5
|
Operating Margin
|
-284.24%
|
18.83%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-15.82
|
4.618
|
-22.54
|
-22
|
-29.88
|
-30.88
|
-32.4
|
-49.88
|
-29.49
|
-28.02
|
-29.78
|
-30.61
|
-31.52
|
-35.7
|
-36.8
|
Net income
1 |
-15.81
|
4.618
|
-22.54
|
-22
|
-29.88
|
-30.88
|
-32.4
|
-49.88
|
-29.49
|
-28.02
|
-29.78
|
-30.61
|
-31.52
|
-35.7
|
-36.8
|
Net margin
|
-289.19%
|
18.48%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.4700
|
0.1000
|
-0.5600
|
-0.5300
|
-0.7200
|
-0.7200
|
-0.7500
|
-1.160
|
-0.6900
|
-0.3500
|
-0.3720
|
-0.3800
|
-0.3900
|
-0.3800
|
-0.2900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/15/22
|
5/12/22
|
8/10/22
|
11/8/22
|
3/15/23
|
5/9/23
|
8/9/23
|
11/8/23
|
3/19/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-63.6
|
-
|
-98.2
|
-75
|
-85.2
|
-91.5
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-23.4%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-20.8%
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
334.8
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
13
|
-
|
4.46
|
7.09
|
7.76
|
6.91
|
Capex / Sales
|
-
|
134.08%
|
-
|
-
|
113.49%
|
93.12%
|
55.28%
|
Announcement Date
|
3/11/21
|
3/15/22
|
3/15/23
|
3/19/24
|
-
|
-
|
-
|
Average target price
9.6
USD Spread / Average Target +585.71% Consensus |
1st Jan change
|
Capi.
|
---|
| -25.93% | 115M | | +29.77% | 49.46B | | +1.00% | 42.58B | | +49.84% | 42.49B | | -5.26% | 29.09B | | +13.68% | 26.61B | | -22.99% | 18.64B | | +8.22% | 13.16B | | +32.41% | 12.55B | | +24.01% | 12.1B |
Other Biotechnology & Medical Research
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly** -40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff** BENEFIT NOW**0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions** #252525**/registration/member/**Blanc**1**7**To continue browsing, please register!**#ffffff50**14px**#33d251**
|